Description

GF-1 LR3 1mg Peptide Description

IGF-1 LR3 (Long Arg³ Insulin-like Growth Factor-1) is a research-grade synthetic analog of human IGF-1 supplied as a lyophilized powder (typically 1mg per vial). It is designed exclusively for in-vitro and preclinical laboratory studies on anabolic signaling, muscle hypertrophy, cartilage regeneration, and metabolic pathways.

Composition

• Active Ingredient: IGF-1 LR3 acetate
  • Sequence: MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA
  • Modifications:
    • Arg³ (Arginine at position 3) → resists binding to IGFBPs
    • 13-amino-acid N-terminal extension → dramatically increases half-life
• Purity: ≥99% (HPLC & MS verified; third-party COA required)
• Molecular Weight: 9,117 Da
• Molecular Formula: C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
• Form: White lyophilized powder
• Storage:
  • Lyophilized: –20°C, desiccated, light-protected (stable 2+ years)
  • Reconstituted: 2–8°C for up to 30 days; avoid freeze-thaw cycles

The 1mg vial supports precise micro-dosing in cell culture or animal models.

Mechanism of Action

IGF-1 LR3 binds IGF-1 receptors (IGF1R) with high affinity, activating PI3K/Akt/mTOR and MAPK/ERK pathways to promote:

• Protein synthesis (via mTORC1)
• Cell proliferation & survival (Akt-mediated anti-apoptosis)
• Glucose uptake (GLUT4 translocation)
• Collagen & ECM production (chondrocytes, fibroblasts)

Key Advantage Over Native IGF-1:

• Half-life: ~20–30 hours (vs. <10 minutes for IGF-1)
• Bioavailability: Minimal binding to IGFBP-3 → sustained systemic activity

Research Applications

Warning: Long-term use may promote hyperplasia or tumor growth in oncogene-expressing models. Contraindicated in cancer research without strict controls.

Research Protocols

• Reconstitution:
  1. Use 0.6% acetic acid or bacteriostatic water + 0.1% HSA/BSA
  2. Add 1 mL solvent → 1 mg/mL (1000 µg/mL) stock
  3. Gently swirl — do NOT shake (prevents denaturation)
  4. Aliquot and store at –80°C for long-term
• Dosing (Animal Models):
  • Systemic: 10–100 µg/kg/day (subcutaneous or intramuscular)
  • Local: 1–5 µg per injection site (e.g., tendon, joint)
  • Cell Culture: 10–100 ng/mL in media
• Administration:
  • Subcutaneous (most common)
  • Intramuscular (targeted hypertrophy)
  • Intra-articular (joint studies)
• Cycle: 2–6 weeks; avoid chronic exposure (>8 weeks) due to receptor desensitization risk.

Safety & Handling

• Stability: Sensitive to pH >7 and proteases; use acidic solvent
• Side Effects (Models): Hypoglycemia, organomegaly (liver, spleen), injection-site fibrosis
• Contraindications:
  • Active malignancy models
  • Diabetic models (risk of severe hypoglycemia)
  • Pregnancy or lactation analogs
• Lab Safety: Treat as biohazard; use PPE; dispose per institutional guidelines